Summary
65 / 100 · Bulios Score
What speaks for it
- Revenue grew by 46% a year over the last 3 years.
- It holds more cash than debt: $690.9M against $452.4M.
- It earns 15 USD a year on every 100 USD of invested capital.
- Analysts expect revenue to grow by 27% this fiscal year.
What to watch
- You pay 85.4 USD for 1 USD of yearly profit, a lot for its sector.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveToday you pay 85.4 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Revenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 46% a year over the last 3 years. For the next fiscal year analysts expect revenue to grow by 27%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 30 USD
- Research and development 9.2 USD
- Sales and administration 45 USD
- Taxes and other 4.9 USD
- Net profit 11 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 11 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 3.1 years of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $26 is 15% below today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.